Breaking News

OncoNano, Regeneron Enter Clinical Trial Supply Pact

Regeneron will supply cemiplimab for Phase 1b segment of OncoNano's ONM-501 trial in patients with advanced solid tumors and lymphomas.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

OncoNano Medicine, Inc. entered a clinical trial supply agreement with Regeneron for the use of Libtayo (cemiplimab), a PD-1 inhibitor, in the combination stage of the first human trial of ONM-501, a dual-activating STING (STimulator of INterferon Genes) agonist and lead therapeutic development candidate.   The ONM-501 trial is a multicenter Phase 1a/b dose escalation and dose expansion study of intratumoral ONM-501 as monotherapy and in combination with Libtayo in patients with advanced solid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters